Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies

Publications

DNA prime and peptide boost immunization elicits robust neoantigen-specific CD8 + T cell responses and therapeutic protection in mouse tumor models.

Journal article

Morgado-Cáceres P. et al, (2026), Oncoimmunology, 15

A first-in-human phase 1 clinical trial evaluating clinical activity and proof-of-mechanism of tobemstomig, a PD1-LAG3 bispecific antibody, in patients with CPI-experienced melanoma.

Journal article

Garralda E. et al, (2026), Clinical cancer research : an official journal of the American Association for Cancer Research

Upstream ORFs control TNFR1 abundance and tissue tolerance to TNF.

Journal article

Ma B. et al, (2026), Science immunology, 11

Using peptide-exchange systems to interrogate peptide-specific KIR binding to HLA Class I

Preprint

Murali TM. et al, (2026)

Intratumoral heterogeneity and immunotherapy resistance: clinical implications.

Journal article

Keenan BP. et al, (2026), Annals of oncology : official journal of the European Society for Medical Oncology, 37, 314 - 328

Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab.

Journal article

Sanmamed MF. et al, (2026), Clinical cancer research : an official journal of the American Association for Cancer Research, 32, 1036 - 1045

Chromosomal instability shapes the tumor microenvironment of esophageal adenocarcinoma via a cGAS-chemokine-myeloid axis.

Journal article

Beernaert B. et al, (2026), Science advances, 12

Risk Factors of Metabolic Dysfunction-associated Steatotic Liver Disease in a Cohort of Patients With Chronic Hepatitis B.

Journal article

Kalafateli M. et al, (2026), Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 24, 701 - 712.e8

Fine-tuning BACH2 dosage balances stemness and effector function to enhance antitumor T cell therapy.

Journal article

Conti AG. et al, (2026), Nature immunology, 27, 436 - 451

Tumor-targeted 4-1BB costimulation enhances immune activation and clinical activity of a CEA-directed T-cell engager in microsatellite-stable colorectal cancer

Preprint

Boehnke A. et al, (2026)

Supplementary Table 1 from Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen–Positive Advanced/Metastatic Solid Tumors

Other

Melero I. et al, (2026)

Data from Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen–Positive Advanced/Metastatic Solid Tumors

Other

Melero I. et al, (2026)

Supplementary Figure 5 from Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen–Positive Advanced/Metastatic Solid Tumors

Other

Melero I. et al, (2026)

Figure S8 from Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen–Positive Advanced/Metastatic Solid Tumors

Other

Melero I. et al, (2026)

Supplementary Methods 1 from Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen–Positive Advanced/Metastatic Solid Tumors

Other

Melero I. et al, (2026)

Load More